Summary In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was given as an i.v. bolus injection at 2 mg m 2 once every 3 weeks in an outpatient setting. Prophylactic antiemetics were not routinely given. Of the 29 eligible patients, nine had been treated surgically and three had received radiotherapy. The main toxic effects observed were stomatitis (34% of cycles) and neutropenia (41% of cycles). Neutropenic fever was rare (3% of cycles). Twenty-seven patients were evaluable for response. There were four partial responses (15%), while 13 patients (48%) showed stabilisation of their disease. The median duration of response was 7 months (range 6.0-10.7 months) and median survival from the start of rhizoxin treatment was 6 months (range 2-14.7 (Thomas and Rubinstein, 1990) . Unfortunately, only a small minority (15-25%) of patients with NSCLC (squamous cell carcinoma, adenocarcinoma and large-cell anaplastic carcinoma), are diagnosed with locally amenable disease and, even for these, about 50% of patients ultimately die from their disease, despite potentially curative interventions. The outcome of chemotherapy for disseminated NSCLC is disappointing. The activity of single agents has been extensively tested in NSCLC with response rates ranging from 5-23% (Bakowski and Crouch, 1983; Cohen and Perevodchikova, 1979; Joss et al., 1984; Cerny et al., 1994) .
Despite major efforts made over many years to improve the diagnosis, prevention and treatment of lung cancer, it remains the leading cause of cancer-related deaths in both men and women in many countries. Surgery offers the best chance of curing early non-small-cell lung cancer (NSCLC) (Thomas and Rubinstein, 1990) . Unfortunately, only a small minority (15-25%) of patients with NSCLC (squamous cell carcinoma, adenocarcinoma and large-cell anaplastic carcinoma), are diagnosed with locally amenable disease and, even for these, about 50% of patients ultimately die from their disease, despite potentially curative interventions. The outcome of chemotherapy for disseminated NSCLC is disappointing. The activity of single agents has been extensively tested in NSCLC with response rates ranging from 5-23% (Bakowski and Crouch, 1983; Cohen and Perevodchikova, 1979; Joss et al., 1984; Cerny et al., 1994) .
The role of combination chemotherapy in NSCLC is still a matter of debate, because despite increased response rates and possible symptom relief, the median survival time is still poor (Rapp et al., 1988; Bonomi et al., 1989) . Therefore the further development of new active agents for NSCLC is of great importance.
Rhizoxin is a novel compound isolated in Japan in the early 1980s from the plant pathogenic fungus Rhizopus chinesis (Hendriks et al., 1992) , which causes rice seedling blight. Rhizoxin is a 16-membered macrolide compound with antifungal and antineoplastic activity. Rhizoxin has been selected for study in clinical trials because of its broadspectrum activity in preclinical studies against murine tumours and human tumour xenografts, its unique interaction with tubulin, which prevents microtubule formation and inhibits mitosis, and its clear anti-tumour activity in the vincristine-resistant P-glycoprotein-expressing tumour cell line (Tsuruo et al., 1986) .
In phase I studies, rhizoxin was administered as an i.v. bolus injection every 3 weeks, and the dose was increased from 0.8 mg m-2 up to 2.6 mg m-2. Neutropenia, mucositis and diarrhoea appeared dose related and dose limiting. The maximum tolerated dose was 2.6 mg m-2 and a dose of 2.0 mg m-2 was recommended for phase II studies (Bissett et al., 1992) .
The EORTC-ECTG has conducted a multicentre prospective phase II trial aiming to assess response to therapy, response duration and toxicity of rhizoxin in patients with advanced NSCLC.
Patients and methods
The study was conducted in accordance with the declaration of Helsinki. The study was approved by the local ethics committee for each centre. Patients gave written informed consent to take part in this study.
To The response to therapy was assessed according to the standard WHO criteria. The first response evaluation was performed 6 weeks after entry into the study. Progression could not be defined before 3 weeks (one full cycle). A progression observed between 3 and 6 weeks after study entry was defined as 'early progression'. Treatment Each vial containing 5 mg of rhizoxin was reconstituted in 2.5 ml of special diluent composed of 80% propylene glycol and 20% ethanol. After complete dissolution had been obtained, 2.5 ml of sterile water for injection was added to produce a solution containing 1 mg ml-'. Further dilution was not permitted as the drug precipitates in saline and dextrose solutions. Rhizoxin was administered at a dose of 2 mg m-2, as a bolus, by direct i.v. injection, once every 3 weeks in an outpatient setting. Dose modification Dose reduction was based upon haematological toxicity. A treatment delay of 1 week was required if on day 22 the leucocyte count was < 3 x 109 I`or the platelets count was < 100 x 109 1-'.
When such a delay occurred the dose was reduced by 25% of the previous dose. Dose reduction was mandatory under these circumstances. The dose was reduced in the same way in the case of documented episodes of either bleeding with thrombocytopenia or febrile neutropenia requiring hospitalisation. For all other grade 2 non-haematological toxicity, such as skin reaction, stomatitis, asthenia, nausea and vomiting or phlebitis, a dose reduction of 25% was left to the discretion of the investigator. If the treatment had to be delayed for more than 2 weeks, the patient was withdrawn from the study. No prophylactic antiemetics were given for the first cycle. If nausea and vomiting occurred conventional antiemetics were given prophylactically for subsequent cycles.
Results
Thirty-one patients were entered into the study between April 1993 and February 1994. Twenty-seven patients were eligible and had evaluable data. Two patients were ineligible and two patients were not evaluable ( Table I) . The reasons for noneligibility were: lack of measurable lesions (one patient) and too long a time interval (> 14 days) between the pretreatment work-up, including tumour assessment, and start of the study drug (one patient). Reasons for non-evaluability were an early death on day 13 of the study due to an allergic reaction to the contrast medium leading to a cardiac arrest while undergoing a venogram (one patient) and a pleurodesis with mitoxanthrone for pleural effusion after first study drug 
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Rhizoxin in non-small-cell lung cancer S Kaplan et al S 405 of the courses respectively. Diarrhoea, headache, allergic hypersensitivity reactions and changes in taste were also registered but their occurrence was rare and of mild nature.
Response to rhizoxin (Table IV) The treatment response was evaluated initially after two courses of chemotherapy and thereafter following every two cycles. Four (14.8%) of 27 patients evaluable for response [95% confidence interval (CI) 4.2-33.7%] showed a partial response (all of bidimensional measurable lesions) to rhizoxin. All objective responses were validated by independent external review. Stable disease was found in 13 patients (48%), while ten patients (37%) progressed during treatment.
Duration of response (partial response and no change) and duration of survival were calculated from the start of treatment. The responses lasted 6, 6.4, 8 and 10.7 months. The median survival was 6 months (range 2-14.7).
Discussion
This phase II study has demonstrated that rhizoxin as a single agent is active in NSCLC. It yielded a response rate of 15% validated by an independent external review, which places rhizoxin among the drugs regarded as active in this tumour type. Rhizoxin given i.v. at 2 mg m-2 every 3 weeks to patients with advanced, non-resectable or metastatic NSCLC, in good performance status, is generally well tolerated. Haematological toxicity, confirming the results of the phase I studies, was modest. Leucopenia and neutropenia CTC grades 3 and 4 were observed in 8% and 15% of the courses respectively, and was rarely associated with infections. It was possible to give the majority of the 118 courses, at a full dose, with only 7% requiring dose reduction due to haematological toxicity. The most common symptomatic toxicity was alopecia (90%). Stomatitis, asthenia and skin manifestation were reported in 30-35% of the courses, mainly of mild severity. Nausea was encountered in 21% of the courses and vomiting in 5% of courses, but were generally not troublesome. Phlebitis and pain radiating along the vein from the injection site was noted in 21% of the courses; two patients required a prolonged administration time. For one patient pethidine administration was necessary for pain control during injection.
Rhizoxin is a new chemotherapeutic agent with a unique mechanism of action, showing activity in NSCLC. Its modest haematological and symptomatic toxicity makes rhizoxin an attractive drug to investigate further in combination chemotherapy and as an outpatient palliative treatment.
